Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting [Yahoo! Finance]
Theratechnologies Inc. - Common Shares (THTX)
Company Research
Source: Yahoo! Finance
Part 3 of Phase 1 trial in advanced ovarian cancer is ongoing MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will present long-term efficacy, safety and pharmacokinetic (PK) data on the use of its lead investigational peptide-drug conjugate (PDC) candidate, TH1902 (sudocetaxel zendusortide), in patients with solid tumors. The Company will present the long-term data in a poster session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which takes place May 31-June 4, 2024, in Chicago, IL. The ASCO poster represents the first presentation of long-term data from Part 1 (dose escalation) and Part 2 (dose expansion) of Theratechnologies' Phase 1 clinical trial of sudocetaxel zendusortide in individuals with solid tumors, following preliminary evidence of a
Show less
Read more
Impact Snapshot
Event Time:
THTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
THTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
THTX alerts
High impacting Theratechnologies Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
THTX
News
- Theratechnologies Reports on its Annual Meeting of Shareholders [Yahoo! Finance]Yahoo! Finance
- Theratechnologies Reports on its Annual Meeting of Shareholders [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Theratechnologies Reports on its Annual Meeting of ShareholdersGlobeNewswire
- Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO MeetingGlobeNewswire
THTX
Sec Filings
- 5/10/24 - Form 6-K
- 5/9/24 - Form 6-K
- 4/15/24 - Form 6-K
- THTX's page on the SEC website